aTyr Pharma appoints David Weiner as Chief Medical Officer

aTyr Pharma, a rare disease biotherapeutics enterprise, has announced the appointment of David Weiner as chief medical officer.

Dr Weiner (pictured) has previously held key leadership positions at Proteostasis, Merck Serono and Acadia Pharmaceuticals. His background includes rare disease and extensive clinical trial experience. Dr Weiner will spearhead aTyr's efforts to advance its Physiocrine biology into meaningful therapeutics to treat rare, grave immune disorders.

“At a key time for advancing our pipeline of therapeutics in the rare diseases arena, Dr Weiner brings to our team a strong drug development background and important clinical experience, and he will lead, implement and execute aTyr's clinical development programs,” said John Mendlein, chief executive and executive chairman of aTyr Pharma. “We welcome Dr Weiner to the team. He is driven to make life changing therapies for patients and will play an important role in our quest for meaningful medicines for patients with little or no treatment options at this time.”